Mereo BioPharma Group plc

NasdaqCM:MREO Stok Raporu

Piyasa değeri: US$657.4m

Mereo BioPharma Group Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Mereo BioPharma Group's earnings are forecast to decline at 11.7% per annum while its annual revenue is expected to grow at 53.3% per year. EPS is expected to grow by 45.8% per annum.

Anahtar bilgiler

-11.7%

Kazanç büyüme oranı

45.8%

EPS büyüme oranı

Biotechs kazanç büyümesi27.1%
Gelir büyüme oranı53.3%
Gelecekteki özkaynak getirisin/a
Analist kapsamı

Low

Son güncelleme13 Aug 2024

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Is Mereo BioPharma Group (NASDAQ:MREO) Weighed On By Its Debt Load?

Apr 07
Is Mereo BioPharma Group (NASDAQ:MREO) Weighed On By Its Debt Load?

Is Mereo BioPharma Group (NASDAQ:MREO) Using Debt Sensibly?

Nov 25
Is Mereo BioPharma Group (NASDAQ:MREO) Using Debt Sensibly?

Mereo stock rises 12% on FDA fast-track status for lung disease drug alvelestat

Oct 17

Rubric Capital boosts Mereo BioPharma board nominees slate to five

Oct 03

Mereo BioPharma: An Activist Pressure With A Potentially Significant Upside

Sep 22

Mereo activist investor Rubric asks board again to hold general meeting, nominate directors

Sep 14

Mereo BioPharma Group regains compliance with Nasdaq's listing rule

Jul 05

Mereo BioPharma: Activist Pressure In A Net-Net Biopharma

Jun 17

Mereo BioPharma: Anti-TIGIT Developer In Mid-Stage Development

Dec 08

Mereo BioPharma and Cancer Focus Fund ink partnership for ovarian cancer study

Apr 30

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:MREO - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/202641-40N/AN/A3
12/31/202516-36N/AN/A5
12/31/202415-23N/AN/A5
6/30/20241-37-21-20N/A
3/31/202410-26-21-20N/A
12/31/202310-29-22-21N/A
9/30/202310-32-34-33N/A
6/30/20239-32-42-42N/A
3/31/2023N/A-42-46-46N/A
12/31/2022N/A-42-47-49N/A
9/30/2022N/A-31-42-43N/A
6/30/2022N/A-23-40-41N/A
3/31/202224-4-25-26N/A
12/31/20214917-8-7N/A
9/30/202149-10-9-8N/A
6/30/202150-37-10-10N/A
3/31/202125-131-23-25N/A
12/31/2020N/A-224-36-39N/A
9/30/2020N/A-198-35-37N/A
6/30/2020N/A-177-34-36N/A
3/31/2020N/A-111-46-47N/A
12/31/2019N/A-46-61-61N/A
9/30/2019N/A-41-50-50N/A
6/30/2019N/A-40-45-45N/A
3/31/2019N/A-41-38-38N/A
12/31/2018N/A-41-30-29N/A
9/30/2018N/A-42-41-39N/A
6/30/2018N/A-44-51-48N/A
3/31/2018N/A-50N/A-48N/A
12/31/2017N/A-52N/A-43N/A
9/30/2017N/A-50N/A-41N/A
6/30/2017N/A-47N/A-39N/A
3/31/2017N/A-41N/A-37N/A
12/31/2016N/A-35N/A-37N/A
6/30/2016N/A-39N/A-25N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: MREO is forecast to remain unprofitable over the next 3 years.

Kazançlar ve Piyasa: MREO is forecast to remain unprofitable over the next 3 years.

Yüksek Büyüme Kazançları: MREO is forecast to remain unprofitable over the next 3 years.

Gelir ve Pazar: MREO's revenue (53.3% per year) is forecast to grow faster than the US market (8.9% per year).

Yüksek Büyüme Geliri: MREO's revenue (53.3% per year) is forecast to grow faster than 20% per year.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if MREO's Return on Equity is forecast to be high in 3 years time


Büyüyen şirketleri keşfedin